Embecta（EMBC）株式概要
医療機器メーカーであるエンベクタ社は、糖尿病患者の健康と福祉を改善するソリューションを米国内外で提供している。 詳細
EMBC Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Embecta Corp. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$3.32 |
| 52週高値 | US$15.55 |
| 52週安値 | US$2.77 |
| ベータ | 1.05 |
| 1ヶ月の変化 | -63.99% |
| 3ヶ月変化 | -67.83% |
| 1年変化 | -70.52% |
| 3年間の変化 | -87.87% |
| 5年間の変化 | n/a |
| IPOからの変化 | n/a |
最新ニュース
Recent updates
ナラティブの更新 • May 16
EMBC: Reset Expectations And Capital Returns Will Shape The Bullish Case
Analysts have reset Embecta's fair value estimate from $25 to $11, reflecting lower price targets after recent cuts from firms that cited updated views on growth, profitability and risk. Analyst Commentary Recent research updates point to a more cautious stance on Embecta's valuation, with several firms lowering their price targets and, in at least one case, issuing a downgrade.
ナラティブの更新 • Apr 30
EMBC: Wound Care Expansion Will Support Future Upside Despite Lower Price Targets
Analysts have trimmed their targets on Embecta by $2 to $3, citing updated expectations that align with an unchanged fair value estimate of $15, a steady discount rate of 12.33%, and consistent long term assumptions for revenue trends, profit margin, and a future P/E of about 7.9x. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed fair value estimate of $15 and implied P/E of about 7.9x as leaving room for the share price to close part of the gap if execution on the existing plan remains consistent.ナラティブの更新 • Apr 15
EMBC: Higher Discount Rate And Wound Care Expansion Will Support Future Upside
Analysts have adjusted Embecta's implied fair value price target from $16.67 to $15.00, reflecting updated views on discount rates, revenue trends, profit margins and future P/E assumptions following recent research, including price target cuts from both Mizuho and BTIG. Analyst Commentary Recent research updates point to a more cautious stance on Embecta, with the lower implied fair value aligning with trimmed price targets and more conservative assumptions around growth, profitability and P/E levels.Seeking Alpha • Mar 19
Embecta: An Interesting Deal At An Interesting Time
Summary Embecta trades at multi-year lows due to GLP-1 overhang and flat sales but maintains strong margins and a >6% dividend yield. Embecta's £150M acquisition of Owen Mumford adds higher-growth exposure, is strategically sound, and is priced at a reasonable 1.4–2x sales multiple. Leverage will rise to 3.3x EBITDA post-deal but appears manageable given stable cash flows and robust profitability. I am cautiously upbeat, seeing deep value at 3x earnings, but prefer a small position due to near-term dilution and leverage concerns. Read the full article on Seeking Alpha
ナラティブの更新 • Feb 18
EMBC: Future M&A And Margin Pressures Will Shape Balanced Outlook
Analysts have maintained Embecta's price target at $11.00, citing updated assumptions that include a slightly lower discount rate, softer revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Embecta is actively exploring mergers and acquisitions, with leadership emphasizing a focus on chronic care drug delivery where the company can use its manufacturing strengths and growing B2B channel (Key Developments).分析記事 • Feb 12
Embecta's (NASDAQ:EMBC) Solid Earnings Have Been Accounted For Conservatively
The market seemed underwhelmed by the solid earnings posted by Embecta Corp. ( NASDAQ:EMBC ) recently. We have done...分析記事 • Feb 09
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 2.4% to close at US$10.87 following the...分析記事 • Feb 08
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 17th of...ナラティブの更新 • Feb 03
EMBC: Future M&A Plans Will Test Balance Sheet And Earnings Multiple
Analysts now hold their fair value estimate for Embecta at US$11.00. The unchanged target reflects modest tweaks to assumptions around revenue growth, profit margin and future P/E that offset the slightly higher discount rate.ナラティブの更新 • Jan 20
EMBC: Future M&A Ambitions Will Heighten Risk Against Weak Earnings Multiple
Analysts have kept their fair value estimate for Embecta steady at US$11.00 while slightly adjusting underlying assumptions around discount rate, revenue growth, profit margins, and forward P/E. This reflects updated views on the company’s risk profile and earnings power without a change to the headline target.分析記事 • Jan 09
Market Cool On Embecta Corp.'s (NASDAQ:EMBC) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...ナラティブの更新 • Jan 05
EMBC: Medium Term Guidance Will Balance Revenue Outlook With Margin Pressures
Analysts have modestly trimmed their price target on Embecta to 11.00 dollars, reflecting slightly higher discount rate assumptions and a marginally lower anticipated future P or E multiple, partially offset by incrementally stronger expectations for revenue growth and profit margins. What's in the News Embecta issued new fiscal 2026 guidance, projecting reported revenues between 1,071 million and 1,093 million dollars, signaling confidence in its medium term growth trajectory (Key Developments).ナラティブの更新 • Dec 15
EMBC: Outlook Will Balance Stabilizing Revenues With Pressured Profit Margins Through 2026
Analysts have modestly raised their price target on Embecta to 11.00 dollars from 11.00 dollars. This reflects improved expectations for a return to positive revenue growth and a higher future earnings multiple, partially offset by a higher discount rate and slightly lower projected profit margins.分析記事 • Nov 28
US$16.67: That's What Analysts Think Embecta Corp. (NASDAQ:EMBC) Is Worth After Its Latest Results
It's been a sad week for Embecta Corp. ( NASDAQ:EMBC ), who've watched their investment drop 14% to US$12.57 in the...分析記事 • Nov 01
Is Now The Time To Look At Buying Embecta Corp. (NASDAQ:EMBC)?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it saw a significant share price rise of 36...分析記事 • Sep 26
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 99% Above Its Share Price
Key Insights The projected fair value for Embecta is US$27.21 based on 2 Stage Free Cash Flow to Equity Embecta's...分析記事 • Aug 28
Even With A 29% Surge, Cautious Investors Are Not Rewarding Embecta Corp.'s (NASDAQ:EMBC) Performance Completely
Despite an already strong run, Embecta Corp. ( NASDAQ:EMBC ) shares have been powering on, with a gain of 29% in the...ナラティブの更新 • Aug 10
GLP-1 Partnerships Will Expand Global Healthcare Reach
The consensus price target for Embecta has been cut from $18.33 to $16.00, primarily reflecting lowered revenue growth forecasts and a declining future P/E multiple. What's in the News Embecta Corp.分析記事 • Jul 04
Sentiment Still Eluding Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 11.4x might make it look like a buy right now...分析記事 • May 22
Embecta (NASDAQ:EMBC) Has Announced A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...分析記事 • May 09
What Is Embecta Corp.'s (NASDAQ:EMBC) Share Price Doing?
Embecta Corp. ( NASDAQ:EMBC ), is not the largest company out there, but it led the NASDAQGS gainers with a relatively...分析記事 • Mar 06
Embecta Corp.'s (NASDAQ:EMBC) Intrinsic Value Is Potentially 87% Above Its Share Price
Key Insights Embecta's estimated fair value is US$24.29 based on 2 Stage Free Cash Flow to Equity Current share price...Seeking Alpha • Feb 28
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour
Summary Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. However, the expanding diabetes care market should partially offset these headwinds, leading to flat topline growth in the coming years. Even though the company is going to post a flat topline, its valuation is such that the business is going to go bust in some time. This situation offers a good risk reward to go long on the stock. Read the full article on Seeking AlphaSeeking Alpha • Dec 04
New Initiatives Expected To Make Embecta More Profitable
Summary Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. I have upgraded the rating on EMBC stock to a Buy, expecting a 12.0% share price increase over the next year, driven by restructuring and new revenue streams. Read the full article on Seeking Alpha分析記事 • Nov 29
Embecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15
Embecta Corp. ( NASDAQ:EMBC ) will pay a dividend of $0.15 on the 18th of December. The dividend yield will be 2.9...分析記事 • Nov 07
At US$16.33, Is It Time To Put Embecta Corp. (NASDAQ:EMBC) On Your Watch List?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...分析記事 • Sep 24
It's A Story Of Risk Vs Reward With Embecta Corp. (NASDAQ:EMBC)
Embecta Corp.'s ( NASDAQ:EMBC ) price-to-earnings (or "P/E") ratio of 12.6x might make it look like a buy right now...
新しいナラティブ • Sep 16
Expanding Global Leadership In Insulin Devices Fuels Revenue Growth And Operational Efficiencies
Strengthening the base business in insulin injection devices suggests potential for stable, growing revenues as the global demographic needing these devices increases.分析記事 • Aug 16
Embecta (NASDAQ:EMBC) Will Pay A Dividend Of $0.15
The board of Embecta Corp. ( NASDAQ:EMBC ) has announced that it will pay a dividend of $0.15 per share on the 13th of...分析記事 • Aug 14
Embecta Corp. Just Beat EPS By 79%: Here's What Analysts Think Will Happen Next
Investors in Embecta Corp. ( NASDAQ:EMBC ) had a good week, as its shares rose 3.1% to close at US$14.82 following the...分析記事 • Jul 13
When Should You Buy Embecta Corp. (NASDAQ:EMBC)?
While Embecta Corp. ( NASDAQ:EMBC ) might not have the largest market cap around , it led the NASDAQGS gainers with a...分析記事 • May 12
Earnings Beat: Embecta Corp. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Embecta Corp. ( NASDAQ:EMBC ) investors will be delighted, with the company turning in some strong numbers with its...株主還元
| EMBC | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | 14.5% | 0.3% | 2.5% |
| 1Y | -70.5% | -19.6% | 26.4% |
業界別リターン: EMBC過去 1 年間で-19.6 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: EMBCは、過去 1 年間で26.4 % のリターンを上げたUS市場を下回りました。
価格変動
| EMBC volatility | |
|---|---|
| EMBC Average Weekly Movement | 17.8% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: EMBCの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: EMBCの 週次ボラティリティ は、過去 1 年間で11%から18%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1924 | 1,850 | Dev Kurdikar | www.embecta.com |
医療機器メーカーであるEmbecta Corp.は、糖尿病患者の健康と福祉を向上させるソリューションを米国内外で提供している。同社の製品には、ペン型注射針、注射器、安全注射器具のほか、患者の糖尿病管理を支援するデジタルアプリケーションなどがある。主に卸売業者や販売業者に製品を販売している。以前はBerra Newco, Inc.として知られていた。エンベクタ社は1924年に設立され、ニュージャージー州パーシッパニーに本社を置く。
Embecta Corp. 基礎のまとめ
| EMBC 基礎統計学 | |
|---|---|
| 時価総額 | US$196.97m |
| 収益（TTM） | US$111.90m |
| 売上高(TTM) | US$1.04b |
1.8x
PER（株価収益率0.2x
P/SレシオEMBC は割高か？
公正価値と評価分析を参照収益と収入
| EMBC 損益計算書（TTM） | |
|---|---|
| 収益 | US$1.04b |
| 売上原価 | US$397.00m |
| 売上総利益 | US$645.50m |
| その他の費用 | US$533.60m |
| 収益 | US$111.90m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 1.89 |
| グロス・マージン | 61.92% |
| 純利益率 | 10.73% |
| 有利子負債／自己資本比率 | -211.9% |
EMBC の長期的なパフォーマンスは？
過去の実績と比較を見る| Embecta 配当日 | |
|---|---|
| 配当落ち日 | May 28 2026 |
| 配当支払日 | Jun 15 2026 |
| 配当落ちまでの日数 | 0 days |
| 配当支払日までの日数 | 18 days |
EMBC 配当は確実ですか？
EMBC 配当履歴とベンチマークを見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/26 15:02 |
| 終値 | 2026/05/26 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/09/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Embecta Corp. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |